Publication - Advice and guidance

AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) Vaccine National Protocol

Published: 24 Mar 2021

This protocol is for the supply and administration of AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) to individuals in accordance with the national COVID-19 vaccination programme.

32 page PDF

518.8 kB

32 page PDF

518.8 kB

Contents
AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) Vaccine National Protocol
5. Clinical condition or situation to which this Protocol applies

32 page PDF

518.8 kB

5. Clinical condition or situation to which this Protocol applies

AstraZeneca COVID-19 Vaccine (ChAdOx1-S [Recombinant]) is indicated for active immunisation against COVID-19 disease caused by SARS-CoV-2 virus in accordance with Scottish Government COVID-19 immunisation programme and recommendations given in Chapter 14a of the Immunisation Against Infectious Disease: the 'Green Book' COVID-19: the green book, chapter 14a - GOV.UK (www.gov.uk) and Scottish Government CMO letters relating to COVID-19 vaccination.


Contact

Email: Covid19VaccinePolicyMailbox@gov.scot